Avacta will once again be presenting and exhibiting (Booth 10) at the Biomarkers and Precision Medicine Congress (8th and 9th October) in San Diego, CA. “Using complex-specific Affimer affinity reagents to improve assays against small molecules and peptides” will be presented by CTO, Matt Johnson at 2:50pm, Tuesday 8th October.
Over 200 attendees representing global pharmaceutical companies, leading biotech companies and internationally renowned academic institutions.
Over 40 presentations and case studies on the key issues in translational science, personalised medicine and clinical development.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.